987," explains Dr. Lunsford. "We also have used the Leksell Gamma Knife
B, C and 4C units over the last 20 years. We now use the 4C unit and the
Perfexion unit side by side in the same radiosurgical suite. We continue to
use the original Leksell Gamma Knife U unit for radiobiological research."
Since 1987, UPMC has performed almost 9,000 Leksell Gamma Knife surgeries
and trained over 1,000 neurosurgeons, radiation oncologists,
neuro-otologists and medical physicists in the appropriate usage of the
Leksell Gamma Knife.
UPMC continues to use a full range of Elekta stereotactic systems
including a new Elekta Synergy(R) S system for spinal radiosurgery that is
going online next week. "Elekta has been a very collaborative partner,"
says Dr. Lunsford, "which is critical for the success of both academic
institutions and companies like Elekta, because testing and product
development occurs within these partnerships."
Elekta is an international medical technology group, providing
oncologists, radiation therapists, neurosurgeons and many other medical
specialists with state-of-the-art tools to fight serious disease.
Elekta provides advanced clinical solutions, comprehensive management
and information systems as well as services for improved cancer care and
management of brain disorders.
Elekta's systems and solutions are used in over 4,500 hospitals around
the world. Clinical and information management solutions include, among
others, Leksell Gamma Knife(R) for non-invasive treatment of brain
disorders, Elekta Axesse(TM) and Elekta Synergy(R) for stereotactic and
image guided radiation therapy and radiosurgery as well as the MOSAIQ(TM)
suite of software for image-enabled EMR and efficient management of
clinical and patient data.
With over 2,000 employees globally, the corporate headquarter is
located in Stockholm, Sweden and the company is listed on the Nordic
Exchange under the ticker EKTAb. More information about Elekta can b
Page: 1 2 3 4 Related medicine technology :1
|SOURCE Elekta, Inc.|
Copyright©2007 PR Newswire.
All rights reserved
. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial2
. Sygnis Pharma AG announces date for presentation of clinical
. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis4
. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis5
. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial6
. BioSante Pharmaceuticals Announces New Findings for Potential Bird
. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis8
. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
. Protox Announces Positive Clinical Data from Prostate Cancer Study11
. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference